u/FitConstruction892

Surely SLS is game to X10 any day now?

I see Sellas Life Sciences has a much bigger, much more impressive network of contributors than I assumed all this time. I probably wouldn't have discovered if it wasn't for a short seller's many sockpuppets harping on their C.E.O. relentlessly and consistently avoiding any mention of anyone else...

NOW I SEE WHY - What a HILARIOUS contrast!

So I'm just giving a few examples of the interesting people contributing to this hopeful revolution in WT1 targeting capability, but I can see how the two drugs of SLS and all to come after are a huge, decades-in-the-making victory for all involved.

Each of these individuals is worth asking an A.I. “list the accolades and accomplishments of X.”

I welcome others to chime in here about other team members, or about scientists from other companies who you’ve appreciated the work of.

Dr. Larry W. Kwak, Director or the Toni Stephenson Lymphoma Center: Among TIME Magazine's 100 most influential people in the world (2010), for his clinical leadership in developing personalized therapeutic cancer vaccines.

https://connection.asco.org/do/meet-two-worlds-most-influential-people

Dr. David A. Scheinberg, M.D., Ph.D. Memorial Sloan Kettering Cancer Center, ranked #2 U.S. institution for cancer care.

Inventor of over 40 patents and author of over 350 scientific papers and book chapters.

In 2013 was named one of the top 20 “Translational Researchers” globally (https://www.nature.com/articles/nbt.2986) Recipient of too many awards to list here.

From A.I.:

Origin of Galinpepimut-S (GPS): The Center served as the incubator for Galinpepimut-S (GPS)—SELLAS Life Sciences’ lead WT1-targeting cancer vaccine candidate. Dr. Scheinberg's lab engineered the synthetic peptide vaccine to elicit a multi-epitope immune response against the WT1 protein, taking it from molecular design all the way through initial clinical validation.

He was chair of the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center, responsible for:

Pioneering Targeted Alpha Therapies: Under his direction the Center pioneered "targeted atomic nanogenerators.” These constructs use targeted antibodies or peptides to deliver radioactive isotopes (such as Actinium-225 and Bismuth-213) directly inside cancer cells to destroy their DNA while sparing surrounding healthy tissue.

TCR-Mimic (TCRm) Antibodies: His team developed groundbreaking T-cell receptor mimic monoclonal antibodies (such as ESK1). These antibodies can recognize intracellular cancer proteins that are displayed as fragments on the cell surface, opening up previously "undruggable" intracellular targets.

Dr. Linghua Wang

Founding executive director: Center for Cellular Language Intelligence at University of Texas Anderson Cancer Center, a cancer hospital consistently ranked No. 1 by the U.S. News & World Report for over a decade.

Originally an opthamologist after medical school, but within months she followed her husband to Tokyo for his Ph.D program. She was hired in a cancer genetics laboratory, and there felt inspired to earn a Ph.D in cancer genomics in Tokyo. “I realized that studying the cancer genome can transform cancer diagnosis and treatment and help cancer patients. After that, I was hooked on cancer genomics and data science.”

Today, her published work has been cited about 70,000 times. https://scholar.google.com/citations?user=GNZEW3EAAAAJ&hl=en

She helps the SLS team map how patients’ immune systems respond to GPS, and applies her foremost skills and experience in parsing those biomarkers predictive of which patients will benefit most from SLS009.

Dr. Panagiotis Tsirigotis (months ago someone lauded him as TsiriGOATis which gave me a good laugh).

Professor of Medicine at the NKUA and Chief of Leukemia at Attikon University Hospital.

From A.I.: National and Kapodistrian University of Athens (NKUA) routinely ranks in the top 100 globally for research citations per faculty member (and ranks 4th among institutions outside the U.S.), outperforming many wealthy European and U.S. institutions due to massive scientific output in oncology, cardiology, and clinical trials.

Also from A.I. "What makes NKUA’s citation metrics unique globally is its extreme concentration of research firepower.”

Whoa there Gemini.

And lastly, wanted to share what Alex Kentsis had to say. Pediatric oncologist, and professor of pediatrics, pharmacology, and physiology & biophysics, and founding director of the center for developmental oncology at the Memorial Sloan Kettering Cancer Center.

Hearing his perspective of essentially having one foot on each frontline of medical science makes me appreciate the “cognitive code-switching” one must do throughout the year in that line of work. Heck, not just cognitive, but of the heart as well. I hope his research contributes to a much brighter future for all the kids he works with.

22:15 https://www.youtube.com/watch?v=K_kZIWWg9GA